Grow Opportunity

News Medical Research Testing
Avicanna and Santé Cannabis initiate study on musculoskeletal pain and inflammation

The real-world evidence study will be conducted in Montreal, Quebec, with Santé Cannabis and will evaluate the efficacy of the product on patients with musculoskeletal pain and inflammation

December 14, 2022  By Grow Opportunity Staff

(Globe Newswire) Toronto — Avicanna Inc., a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, will be initiating an observational real-world evidence study using RHO Phyto branded Cannabigerol (CBG) transdermal gel on patients with musculoskeletal pain and inflammation together with Santé Cannabis, a clinical research site and contract research organization.

Observational Real-World Evidence Study

The research study will seek to enroll 100 patients and evaluate patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2 per cent Cannabidiol (CBD) and 1 per cent CBG on arthritis including osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and/or joint pain, localized pain, post-surgical pain, muscular and/or structural injuries.

The participants, as identified by the healthcare provider will take part in a three-month study including clinical visits at baseline and three-month follow-up assessment. In addition to demographic, medical history, medication use and overall symptom assessment questionnaires, the patients will complete the musculoskeletal health questionnaire, a validated measure of symptoms and quality of life.

The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider. Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO. The prospective study is expected to launch in early Q1 2023.


RHO Phyto Transdermal CBG Gel

The CBG Transdermal Gel is a part of Avicanna’s RHO Phyto formulary of medical products which includes proprietary oral, sublingual, and topical products containing a range of cannabinoids. The gel includes a combination of CBG and CBD in a fast-absorbing, water-based gel intended for application locally to area of focus. The gel utilizes Avicanna’s deep tissue emulsion technology and combines cannabinoids with synergistic natural ingredients and terpenes including menthol, eugenol and beta-caryophyllene.

Print this page


Stories continue below